Education
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics (CAPR)
NASDAQ:CAPR
CAPR Analyst Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CAPR Stock 12 Month Forecast
Average Price Target
$21.22
▲(159.41%Upside)
| Highest Price Target$29.00 | Average Price Target$21.22 | Lowest Price Target$12.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$8
Hold
-2.20%
Downside
Reiterated
07/31/25
Capricor Therapeutics' overall stock score reflects a challenging financial position with consistent losses and cash flow issues, tempered by strategic advancements and a strong equity position. Technical indicators suggest a lack of strong momentum, and valuation metrics are unfavorable due to a negative P/E ratio. Positive developments in the earnings call and corporate events provide some optimism, but the FDA's CRL presents an immediate challenge.
H.C. Wainwright
$24
Buy
193.40%
Upside
Reiterated
07/30/25
Capricor Therapeutics: Strategic Refinement and Optimism for Deramiocel's FDA ApprovalValuation and potential impediments to achieving it. We reiterate our Buy rating and our price target of $24. Our price target is based on our clinical net present value (NPV) model, which is driven entirely by the company's lead asset, deramiocel, in DMD patients. There is no contribution from added deramiocel indications or future potential exosomes candidates, which we believe represent potential upside to our valuation.
Oppenheimer
$22
Buy
168.95%
Upside
Reiterated
07/22/25
Maxim Group
$25
Buy
205.62%
Upside
Reiterated
07/15/25
Alliance Global Partners
$20→$16
Buy
95.60%
Upside
Reiterated
07/14/25
Roth MKM
$31→$12
Buy
46.70%
Upside
Reiterated
07/14/25
Cantor Fitzgerald
$30→$22
Buy
168.95%
Upside
Reiterated
07/11/25
Piper Sandler
$43→$20
Buy
144.50%
Upside
Reiterated
07/11/25
B.Riley Financial
$21
Buy
156.72%
Upside
Initiated
06/26/25
JonesTrading
$40→$29
Buy
254.52%
Upside
Reiterated
06/24/25
Ladenburg Thalmann & Co.
$48
Buy
486.80%
Upside
Reiterated
03/20/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$8
Hold
-2.20%
Downside
Reiterated
07/31/25
Capricor Therapeutics' overall stock score reflects a challenging financial position with consistent losses and cash flow issues, tempered by strategic advancements and a strong equity position. Technical indicators suggest a lack of strong momentum, and valuation metrics are unfavorable due to a negative P/E ratio. Positive developments in the earnings call and corporate events provide some optimism, but the FDA's CRL presents an immediate challenge.
H.C. Wainwright
$24
Buy
193.40%
Upside
Reiterated
07/30/25
Capricor Therapeutics: Strategic Refinement and Optimism for Deramiocel's FDA ApprovalValuation and potential impediments to achieving it. We reiterate our Buy rating and our price target of $24. Our price target is based on our clinical net present value (NPV) model, which is driven entirely by the company's lead asset, deramiocel, in DMD patients. There is no contribution from added deramiocel indications or future potential exosomes candidates, which we believe represent potential upside to our valuation.
Oppenheimer
$22
Buy
168.95%
Upside
Reiterated
07/22/25
Maxim Group
$25
Buy
205.62%
Upside
Reiterated
07/15/25
Alliance Global Partners
$20→$16
Buy
95.60%
Upside
Reiterated
07/14/25
Roth MKM
$31→$12
Buy
46.70%
Upside
Reiterated
07/14/25
Cantor Fitzgerald
$30→$22
Buy
168.95%
Upside
Reiterated
07/11/25
Piper Sandler
$43→$20
Buy
144.50%
Upside
Reiterated
07/11/25
B.Riley Financial
$21
Buy
156.72%
Upside
Initiated
06/26/25
JonesTrading
$40→$29
Buy
254.52%
Upside
Reiterated
06/24/25
Ladenburg Thalmann & Co.
$48
Buy
486.80%
Upside
Reiterated
03/20/25
Best Analysts Covering Capricor Therapeutics
1 Month
xxx
Success Rate
8/13 ratings generated profit
Average Return
+20.84%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +20.84% per trade.
3 Months
xxx
Success Rate
8/17 ratings generated profit
Average Return
+30.90%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of +30.90% per trade.
1 Year
Success Rate
6/9 ratings generated profit
Average Return
+30.22%
reiterated a buy rating 21 days ago
Copying Kristen Kluska's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +30.22% per trade.
2 Years
xxx
Success Rate
11/16 ratings generated profit
Average Return
+48.04%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 68.75% of your transactions generating a profit, with an average return of +48.04% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CAPR Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
14
12
17
22
29
Buy
0
0
1
1
1
Hold
0
0
4
7
13
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
12
22
30
43
Each month's total comprises the sum of three months' worth of ratings.
CAPR Financial Forecast
CAPR Stock Forecast FAQ
What is CAPR’s average 12-month price target, according to analysts?
Based on analyst ratings, Capricor Therapeutics’s 12-month average price target is 21.22.
What is CAPR’s upside potential, based on the analysts’ average price target?
Capricor Therapeutics has 159.41% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CAPR a Buy, Sell or Hold?
Capricor Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
What is Capricor Therapeutics’s price target?
The average price target for Capricor Therapeutics is 21.22. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $29.00 ,the lowest forecast is $12.00. The average price target represents 159.41% Increase from the current price of $8.18.
The highest analyst price target is $29.00 ,the lowest forecast is $12.00. The average price target represents 159.41% Increase from the current price of $8.18.
What do analysts say about Capricor Therapeutics?
Capricor Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of CAPR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.